Third Pole Logo

  December 14, 2022   Company Press Releases

Funding will support the final development phase prior to planned 2023 FDA submission of the company’s “breakthrough” designated eNOcare™ hospital device Waltham, MA –December 14, 2022 – Third Pole Therapeutics, a privately held company developing critical life-sustaining cardio-pulmonary therapies, announced today a $32M equity investment, from a large medical device innovator. Bill Athenson, CEO of Third Pole, stated, “We are …

  May 28, 2020   News/Publications

The severity of COVID-19 respiratory failure in some patients has taken the medical community by surprise. And in response, that community has been trying just about anything that seems reasonable in an effort to improve outcomes — and in some cases as last-resort measures to save lives.

  April 2, 2020   News/Publications

Scientists in Massachusetts, Italy, and elsewhere are experimenting with a familiar medical treatment for the new problem of covid-19. They’ve begun clinical trials meant to find out whether inhaled nitric oxide can save people who are severely sick from the new coronavirus. This treatment might even be used preventatively to keep health care workers infection-free.